<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00274040</url>
  </required_header>
  <id_info>
    <org_study_id>205.244</org_study_id>
    <nct_id>NCT00274040</nct_id>
  </id_info>
  <brief_title>Comparison of Tiotropium and Ipratropium in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With COPD</brief_title>
  <official_title>A Comparison of 18 μg of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (2 Puffs of 20 μg, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Comparison of 18 mcg of Tiotropium Inhalation Capsules and ipratropiumMetered Dose Inhaler (2&#xD;
      puffs of 20 mcg, four times daily) in a Double-Blind, Double-dummy, Efficacy and Safety Study&#xD;
      in Adults with Chronic Obstructive Pulmonary Disease (COPD).&#xD;
&#xD;
      The objective of this study is to compare the bronchodilator efficacy and safety of&#xD;
      tiotropium inhalation capsules (18 mcg once daily) and ipratropium MDI (2 puffs of 20 mcg&#xD;
      q.i.d.) in patients with chronic obstructive pulmonary disease (COPD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2-treatment, randomized, double-blind, parallel design trial in adult patient with&#xD;
      COPD.&#xD;
&#xD;
      Each dose of tiotropium or placebo will consist of one capsule self administered from the&#xD;
      HandiHaler device once daily during the treatment period (tiotropium or placebo). Each dose&#xD;
      will be taken at the same time each morning between 08:00 a.m. and 10:00 a.m.&#xD;
&#xD;
      Each dose of ipratropium MDI or placebo MDI will consist of 2 puffs; patients will inhale 2&#xD;
      puffs four times daily. The first dose will be taken at the same time each morning between&#xD;
      08:00 a.m. and 10:00 a.m.; subsequent doses will be taken at lunch, at dinner and when going&#xD;
      to bed.&#xD;
&#xD;
      Study Hypothesis:&#xD;
&#xD;
      The null hypothesis is that there is no difference in mean response between tiotropium and&#xD;
      ipratropium.&#xD;
&#xD;
      The alternative hypothesis is that there is a difference in mean response between tiotropium&#xD;
      and ipratropium.&#xD;
&#xD;
      Comparison(s):&#xD;
&#xD;
      This is a multi-center, randomized, double-blind, double-dummy, parallel group trial to&#xD;
      compare the bronchodilator efficacy and safety of Tiotropium (18 mcg once a day) and&#xD;
      ipratropium Metered Dose Inhaler (2 puffs of 18 mcg four times a day).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough FEV1 response: change from baseline FEV1 (visit 2) to visit 4 trough FEV1</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 (AUC0-3) response (change from baseline) for the 3 hours post drug administration</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC response</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC (AUC0-3) response (as defined for FEV1)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient questionnaire</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily PEFR</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of rescue medication</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All adverse events</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs (pulse rate and blood pressure)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormalities in routine blood chemistry, haematology and urinanalysis</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in 12-lead electrocardiogram (ECG)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <enrollment>141</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. All patients must have a diagnosis of chronic obstructive pulmonary disease according&#xD;
             to the following criteria:&#xD;
&#xD;
             Patients must have relatively stable airway obstruction with an FEV1 &gt;= 65% of&#xD;
             predicted normal and FEV1 70% of FVC. &quot;Predicted normal values will be based on&#xD;
             formulas as supplied by the individual study sites.&quot;&#xD;
&#xD;
          2. Male or female patients 40 years of age or older.&#xD;
&#xD;
          3. Patients must have a smoking history of more than 10 pack-years. A pack-year is&#xD;
             defined as the equivalent of smoking one pack of cigarettes per day for a year.&#xD;
&#xD;
          4. Patients must be able to perform pulmonary function tests as required in the protocol.&#xD;
&#xD;
          5. Patients must be able to inhale medication from the HandiHaler device and should have&#xD;
             a good technique of inhaling aerosol administered from an MDI.&#xD;
&#xD;
          6. All patients must sign an Informed Consent Form prior to participation in the trial&#xD;
             i.e., prior to pre-study washout of their usual pulmonary medications&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Patients with significant diseases other than COPD will be excluded. A significant&#xD;
             disease is defined as a disease which in the opinion of the investigator may either&#xD;
             put the patient at risk because of participation in the study or a disease which may&#xD;
             influence the results of the study or the patient's ability to participate in the&#xD;
             study.&#xD;
&#xD;
          2. Patients with clinically significant abnormal baseline hematology, blood chemistry or&#xD;
             urinalysis, if the abnormality defines a disease listed as an exclusion criterion will&#xD;
             be excluded.&#xD;
&#xD;
          3. All patients with a SGOT and SGPT twice the normal range, bilirubin 150% or creatinine&#xD;
             125% of the normal range will be excluded regardless of the clinical condition. Repeat&#xD;
             laboratory evaluation will not be conducted in these subjects.&#xD;
&#xD;
          4. Patients with a recent history (i.e. one year or less) of myocardial infarction.&#xD;
&#xD;
          5. Patients with a recent history (i.e. three years or less) of heart failure or patients&#xD;
             with any cardiac arrhythmia requiring drug therapy.&#xD;
&#xD;
          6. Patients with regular use of daytime oxygen therapy.&#xD;
&#xD;
          7. Patients with known active tuberculosis.&#xD;
&#xD;
          8. Patients with a history of cancer within the last five years. Patients with treated&#xD;
             basal cell carcinoma are allowed.&#xD;
&#xD;
          9. Patients with a history of life-threatening pulmonary obstruction, or a history of&#xD;
             cystic fibrosis or bronchiectasis.&#xD;
&#xD;
         10. Patients who have undergone pulmonary resection or a thoracotomy for any reason.&#xD;
&#xD;
         11. Patients with an upper respiratory tract infection in the past 6 weeks prior to the&#xD;
             Screening Visit (=Visit 1) or during the baseline period of 2-weeks (run-in period).&#xD;
&#xD;
         12. Patients with known hypersensitivity to anticholinergic drugs, lactose or any other&#xD;
             component of the inhalation capsule delivery system or the MDI&#xD;
&#xD;
         13. Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction.&#xD;
&#xD;
         14. Patients with known narrow-angle glaucoma.&#xD;
&#xD;
         15. Patients who are being treated with cromolyn sodium or nedocromil sodium.&#xD;
&#xD;
         16. Patients who are being treated with antihistamines.&#xD;
&#xD;
         17. Patients using oral corticosteroid medication at unstable (i.e. less than 6 weeks on a&#xD;
             stable dose) or at a dose in excess of the equivalent 10 mg of prednisone per day or&#xD;
             20 mg every other day.&#xD;
&#xD;
         18. Pregnant or nursing women or women of childbearing potential not using a medically&#xD;
             approved means of contraception (e.g. oral contraceptives, intrauterine devices, or&#xD;
             diaphragm).&#xD;
&#xD;
         19. Patients with a history of asthma, allergic rhinitis or atopy or who have a blood&#xD;
             total eosinophil count 400&gt;= per mcl (males) or 320&gt;= per mcl (females). A repeat&#xD;
             eosinophil count will not be conducted in these patients.&#xD;
&#xD;
         20. Patients with a history and/or active alcohol or drug abuse.&#xD;
&#xD;
         21. Patients who have taken an investigational drug one month or six half-lives (whichever&#xD;
             is greater) prior to the Screening Visit (=Visit 1).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>B.I. Korea Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeonnam National University Hospital</name>
      <address>
        <city>Kwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan University Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Hosital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangnam St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoungbuk National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyunghee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Asan Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinchon Severence Hosp (Yonsei University Hosp)</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital, Dept. of Respiratory</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Youngdong Sevarence Hospital (Yonsei University Hospital)</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Christian Hospital (Yonsei University Hosp)</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.244_U05-3093.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>January 9, 2006</study_first_submitted>
  <study_first_submitted_qc>January 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2006</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

